Delta Injection Index as a Predictor of Visual Acuity Outcomes in Neovascular AMD patients in a Large Cohort with Long Term Follow-up

Abstract Purpose To investigate the change in Visual acuity (VA) of neovascular Age-related macular degeneration (nAMD) patients throughout three years of follow-up, according to the change in the number of annual anti vascular endothelial growth factor (VEGF) injections. Methods A retrospective, observational study of nAMD patients who were followed up between 06/2015-12/2021. Patients were divided into three groups based on the delta in the number of injections from baseline: no-delta, mid-delta, and high-delta. Results A total of 1,144 patients up met the inclusion criteria and were included in this study. Two hundred and twenty-six eyes were classified for the no-delta injections index group while 475 and 443 eyes were in the mid and high groups, respectively. Number of injections in the first year was similar between all three groups with 6.8 ± 2.3, 7.1 ± 2.0, and 6.9 ± 2.5 for the no-delta, mid-delta, and high-delta group (p = 0.345). Baseline VA was similar between all groups, 0.37 ± 0.31, 0.39 ± 0.31, and 0.41 ± 0.34 (p = 0.115), respectively. Final VA was significantly better for the no-delta group (p = 0.035), as the mid-delta and high-delta injection index groups suffered statistically significant decline in VA throughout three years down to 0.59 ± 0.46, and 0.61 ± 0.50, respectively (p < 0.01), while the no-delta patients experienced only a non-statistically significant decline in their VA to 0.50 ± 0.41 (p = 0.051). Conclusion Delta from baseline of annual anti-VEGF injections for nAMD patients may lead to less favorable visual outcomes with a statistically significant decline in visual acuity for the mid-delta and high delta groups in comparison to the no-delta group.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-16
DOI
https://doi.org/10.21203/rs.3.rs-10329065/v1
Primary Topic
Retinal Diseases and Treatments
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Delta Injection Index as a Predictor of Visual Acuity Outcomes in Neovascular AMD patients in a Large Cohort with Long Term Follow-up

Ram Cohen, Eran Greenbaum, Reut Shor, Shai Cohen et al.
Research Square
Retinal Diseases and Treatments
preprint

Delta Injection Index as a Predictor of Visual Acuity Outcomes in Neovascular AMD patients in a Large Cohort with Long Term Follow-up

Ram Cohen, Eran Greenbaum, Reut Shor, Shai Cohen, Gilad Rabina, Ori Segal, Omer Trivizki, Anat Loewenstein
preprint en

Abstract

Abstract Purpose To investigate the change in Visual acuity (VA) of neovascular Age-related macular degeneration (nAMD) patients throughout three years of follow-up, according to the change in the number of annual anti vascular endothelial growth factor (VEGF) injections. Methods A retrospective, observational study of nAMD patients who were followed up between 06/2015-12/2021. Patients were divided into three groups based on the delta in the number of injections from baseline: no-delta, mid-delta, and high-delta. Results A total of 1,144 patients up met the inclusion criteria and were included in this study. Two hundred and twenty-six eyes were classified for the no-delta injections index group while 475 and 443 eyes were in the mid and high groups, respectively. Number of injections in the first year was similar between all three groups with 6.8 ± 2.3, 7.1 ± 2.0, and 6.9 ± 2.5 for the no-delta, mid-delta, and high-delta group (p = 0.345). Baseline VA was similar between all groups, 0.37 ± 0.31, 0.39 ± 0.31, and 0.41 ± 0.34 (p = 0.115), respectively. Final VA was significantly better for the no-delta group (p = 0.035), as the mid-delta and high-delta injection index groups suffered statistically significant decline in VA throughout three years down to 0.59 ± 0.46, and 0.61 ± 0.50, respectively (p < 0.01), while the no-delta patients experienced only a non-statistically significant decline in their VA to 0.50 ± 0.41 (p = 0.051). Conclusion Delta from baseline of annual anti-VEGF injections for nAMD patients may lead to less favorable visual outcomes with a statistically significant decline in visual acuity for the mid-delta and high delta groups in comparison to the no-delta group.

Research Square
Tel Aviv Sourasky Medical Center (IL), Meir Medical Center (IL)
Good health and well-being
Retinal Diseases and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon